See the DrugPatentWatch profile for tigecycline

There is limited research directly investigating the relationship between pre-existing liver conditions and Tigecycline toxicity. However, it is known that Tigecycline, like many other antibiotics, is primarily metabolized in the liver [1].

The prescribing information for Tigecycline, Tygacil, by Pfizer, does mention that "patients with severe hepatic impairment (Child-Pugh C) have not been studied" and that "the pharmacokinetics of Tigecycline in patients with impaired hepatic function are unknown" [2]. This suggests that caution should be exercised when administering Tigecycline to patients with pre-existing liver conditions.

Moreover, a study published in the Journal of Antimicrobial Chemotherapy found that "Tigecycline clearance was significantly lower in patients with moderate or severe hepatic impairment" [3]. This could potentially lead to increased drug exposure and toxicity.

In conclusion, while there is no definitive answer to whether patients with pre-existing liver conditions are more prone to Tigecycline toxicity, the available information suggests that these patients may require closer monitoring due to potential changes in drug metabolism and clearance.

Sources:
[1] DrugPatentWatch.com, "Tigecycline", https://www.drugpatentwatch.com/drugs/tigecycline
[2] Pfizer, "Tygacil (Tigecycline) Prescribing Information", https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s015s016lbl.pdf
[3] S. J. Curran et al., "Pharmacokinetics of tigecycline in patients with hepatic impairment", Journal of Antimicrobial Chemotherapy, Volume 62, Issue 3, 15 March 2008, Pages 573–578, https://academic.oup.com/jac/article/62/3/573/840807